Alnylam Pharmaceuticals, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 8731 https://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

A Look Into Foreign Direct Investment Trends - Jun 24th, 2022 12:40 pm
The Petri Dish: Amylyx, Alnylam net drug approvals - Jun 16th, 2022 2:11 pm
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod - Jun 14th, 2022 3:12 pm
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults - Jun 13th, 2022 11:22 pm
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study - Jun 10th, 2022 2:51 pm
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy - Jun 9th, 2022 11:00 am
10 Stocks to Buy Before the Next Pandemic - Jun 7th, 2022 1:13 pm
Alnylam to Webcast Presentations at Upcoming June Investor Conferences - Jun 2nd, 2022 8:00 pm
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues - Jun 2nd, 2022 3:42 pm
Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II - Jun 1st, 2022 12:47 pm
Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 94% - May 26th, 2022 12:29 pm
Mass. life sciences leaders urge action on 'epidemic' of gun violence - May 25th, 2022 8:41 pm
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease - May 24th, 2022 5:06 pm
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 - May 24th, 2022 11:00 am
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran - May 23rd, 2022 11:00 am
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition - May 19th, 2022 4:34 pm
Alnylam Announces Health Canada Authorization of OXLUMO™ (lumasiran), the First and Only Treatment for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Paediatric and Adult Patients - May 18th, 2022 12:00 pm
Alnylam to Webcast Presentations at Upcoming May Investor Conferences - May 4th, 2022 12:00 pm
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline - May 2nd, 2022 5:26 pm
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View - Apr 29th, 2022 4:33 pm